Thursday, 14 December 2023

DOCTORS AND EXPERTS AROUND THE WORLD CALL FOR URGENT ACTION TO PREVENT LIVER HEALTH CRISIS

Global Liver Institute’s Second Edition “Global State of Liver Health” Report Reveals Promising Opportunities

Washington D.C., Dec 13 (Bernama-GLOBE NEWSWIRE) --
 Global Liver Institute (GLI), the premier patient-led liver health nonprofit operating globally, released the second edition of its “Global State of Liver Health” report, now including 22 countries covering every region of the world. Following the impetus of the Liver Health is Public Health initiative, international experts drew attention to pressing opportunities for their respective governments to prioritize and improve liver health.

Liver disease continues to pose a heavy burden for the world and its health systems:
“Our continued exploration of the scope and scale of the impact of liver diseases gives us both pause and hope. Powerful human intellect has developed many innovative solutions,” noted GLI CEO Donna R. Cryer, JD. “Rather than let these solutions go to waste, it is now time to direct political will towards putting them into practice and ensuring the ability to achieve liver health – and overall health – around the world.” 

Strategies and technologies currently exist that can prevent liver disease or catch it early. However, putting these tools into practice can require financial investment, expert training, and often complex execution on a scale that necessitates government support. Several of the report’s expert advisors highlighted the policy opportunities and successes that might support liver health:

“We don’t have many tools currently to control tobacco smoking, alcohol consumption, and even the consumption of unhealthy diets in Vietnam,” shared Dr. Tung Pham, report advisor and lecturer /physician at Hanoi Medical University. “These are the second and third leading factors, so a tightening of standards, maybe raising taxes and implementing other promotional programs, will be essential.”

In contrast, a liberal treatment program that provided newly developed hepatitis C treatment to patients in Australia without many barriers has eliminated more than half of the viral disease throughout the country. As report advisor and leading hepatologist Dr. Simone Strasser noted in the report, several features brought about a successful program, including comprehensive training of primary care providers, minimal direct cost to patients, and local access to treatment.

National experts have identified the greatest threats to liver health in their communities. Now, those who care about liver health and its related conditions must urge their national leaders to prioritize and implement solutions.

The Liver Health is Public Health initiative is made possible thanks to the support of Sanofi and Salix Pharmaceuticals.

###

About Global Liver Institute  

Global Liver Institute (GLI) is a 501(c)3 nonprofit organization founded in the belief that liver health must take its place on the global public health agenda commensurate with the prevalence and impact of liver illness. GLI promotes innovation, encourages collaboration, and supports the scaling of optimal approaches to help eradicate liver diseases. Operating globally, GLI is committed to solving the problems that matter to liver patients and equipping advocates to improve the lives of individuals and families impacted by liver disease. GLI holds Platinum Transparency with Candid/GuideStar, is a member of the National Health Council, and serves as a Healthy People 2030 Champion. Follow GLI on FacebookInstagramLinkedIn, and YouTube or visit www.globalliver.org

http://mrem.bernama.com/viewsm.php?idm=47760

Friday, 8 December 2023

ISF NET ESTABLISHES SINGAPORE OFFICE AS IT SEEKS TO STRENGTHEN IT TALENT IN ASIA

SINGAPORE and TOKYO, Dec. 7, 2023 /Kyodo JBN-AsiaNet/ --

- GLOBAL ISF PTE. LTD. to Bolster ISF NET, INC's Regional Presence and Support Its Ambitions in Global Expansion -

ISF NET, INC., a leading Japanese IT services and staffing company, announced on December 7 the establishment of GLOBAL ISF PTE. LTD. in Singapore as it eyes greater business expansion in the Asian region.

Logo:
As part of its expansion into Singapore, ISF NET will invest approximately USD13.5 million (2 billion yen) in the venture, setting a sales target of USD20.3 million (3 billion yen) for the global business. The company aims to hire 150 employees by 2030 to bolster its support for clients in Singapore and other parts of Southeast Asia.

With over two decades of industry experience and with offices in Japan, China and South Korea, ISF NET's entry into Singapore marks a significant step towards strengthening its position in Asia. More significantly, this move represents a strategic shift in ISF NET's focus of services from Japan to the global market.

"As a renowned international talent hub, Singapore offers an ideal gateway for multinational companies aiming to grow in Asia," said Yukiyoshi Watanabe, President and CEO, ISF NET, INC. "I am confident that our foray into Singapore will further strengthen our presence in the region and empower clients with tailored IT infrastructure solutions to help them navigate and succeed in a region as diverse as Asia."

Business Strategy in Singapore
ISF NET's business strategy will focus on providing IT engineering HR support for companies in Singapore and recruiting Japanese-English and Korean-English speaking bilingual IT infrastructure engineers. The engineers will be hired from Singapore and other parts of Asia and will be staffed to IT infrastructure projects in Japan and Korea.

"ISF NET's expansion into Singapore underscores our commitment to uplifting engineering talent across Asia through cross-border knowledge sharing. In tandem with this, we aim to foster a globally connected workforce and alleviate the hiring and skills challenges faced by our clients across Asia," said Kohei Wakamoto, Managing Director of GLOBAL ISF PTE. LTD.

The company aims to address the increasing scarcity of IT talent in Singapore by growing its IT infrastructure-managed service business, IT talent recruitment and IT talent staffing business. This will connect local engineers eager to enhance their skills through overseas projects with companies which are actively seeking bilingual experts.

By fostering collaboration with highly skilled engineers in Singapore and across Asia, ISF NET is committed to delivering advanced projects and cutting-edge technology solutions. As part of future initiatives, ISF NET aims to facilitate remote work for individuals who have relocated from overseas, fostering a flexible and globally connected workforce.

In addition, ISF NET will focus on developing key partnerships with Japanese and Korean companies which are looking to expand in Asia but lack the know-how, resources and talent to do so. Leveraging its decades of experience in IT staffing solutions, ISF NET will support these companies in actively recruiting bilingual engineers to strengthen business partnerships within region. This will help solve challenges faced by these companies, namely the increased difficulty in hiring bilingual IT infrastructure engineers and alleviation of the additional burden on current employees.

Across Asia, ISF NET will provide IT infrastructure services related to cloud, security, and networking, particularly for businesses facing challenges in their digital transformation journey related to human resources, skills, and environmental improvement. 

http://mrem.bernama.com/viewsm.php?idm=47723

Tuesday, 5 December 2023

THE SHANGHAI COOPERATION ORGANIZATION TRADITIONAL MEDICINE FORUM OPENED




NANCHANG, China, Dec. 4, 2023 /Xinhua-AsiaNet/-- 
The Shanghai Cooperation Organization Traditional Medicine Forum opened in Ganjiang New District, Jiangxi Province on November 30, 2023, with the theme of "Inheritance and innovation, unity and cooperation, promoting high-quality development of traditional medicine industry".
 
Source: The Shanghai Cooperation Organization Traditional Medicine Forum 

http://mrem.bernama.com/viewsm.php?idm=47680

Friday, 1 December 2023

BIOSKRYB GENOMICS APPOINTS GENOMICS INDUSTRY VETERAN RAM LAXMAN AS CHIEF COMMERCIAL OFFICER




Ram Laxman brings executive leadership experience from 10x Genomics, Illumina, and Pacific Biosciences to expand BioSkryb’s international footprint


DURHAM, N.C., Nov 30 (Bernama-BUSINESS WIRE) -- BioSkryb Genomics, a company transforming single-cell analysis by enabling the most complete multiomic view of the cellular ecosystem, from discovery to diagnostics, has appointed Ram Laxman, Ph.D., as Chief Commercial Officer. Dr. Laxman will lead sales and support, commercial strategy and operations, and marketing as BioSkryb continues to scale its global presence. He brings strong executive leadership experience and an extensive track record of building and scaling businesses at companies like 10x Genomics, Pacific Biosciences, and Illumina.

This press release features multimedia. View the full release here: 
https://www.businesswire.com/news/home/20231129687097/en/
 
Dr. Laxman joins BioSkryb from 10x Genomics, where he served as the President and General Manager, APAC. As the company’s first hire in APAC, he was instrumental in building 10x Genomics’ presence in the region. He established the Asian operational headquarters in Singapore, oversaw all aspects of the commercial business, managed a team of approximately 100 colleagues across offices in Singapore, Shanghai, and Tokyo, and scaled its APAC revenue to over $100 million.

“BioSkryb has developed a best-in-class DNA-informed single-cell multiomics portfolio that can provide a deeper understanding of the cell-to-cell genomic variability that is critical for the development of more precise and effective treatments for diseases like cancer,” said Dr. Ram Laxman, CCO, BioSkryb Genomics. “Having been at the forefront of genomics and single-cell sequencing, I believe BioSkryb’s technology offers the next big leap in advancing single-cell genomics. Integrated multiomics is the future, and BioSkryb’s technology will play a foundational role in the next decades in discoveries and diagnostics in the broader genomics market. I’m looking forward to scaling BioSkryb’s presence across the globe and driving our commercial pipeline to bring our technology to new users.”

Before 10x Genomics, Dr. Laxman was part of the very early commercial teams at Illumina and Pacific Biosciences. Dr. Laxman holds a Ph.D. in molecular biology and served as a postdoctoral fellow with the eminent Professor Daniel Koshland at the University of California, Berkeley.

“We are excited to welcome Ram to our leadership team and know that his deep expertise in establishing and growing a solid presence for some of the most successful companies in the genomics space will allow us to exponentially increase our international footprint,” said Suresh Pisharody, CEO, BioSkryb. “This year, BioSkryb has experienced a strong growth surge in North America where our focus has been, and with Ram on board, we are poised to drive significant growth for the company and expand the footprint of our industry leading single-cell products globally in the years to come.”

Dr. Laxman’s predecessor, Reagan Tully, has been appointed Chief Business Officer of the organization, leading corporate, business, and market development functions, focused on expansion and adoption of the technology through key partnerships and collaborations across the industry.

These appointments reflect BioSkryb’s continued momentum in advancing single-cell analysis, including the launch of ResolveOME™, a revolutionary multiomic solution, and the first-of-its-kind BaseJumper™ platform for multimodal bioinformatics analysis. Additionally, BioSkryb recently announced a significant distribution agreement to expand its services offering across Singapore and Southeast Asia.

To learn more about BioSkryb, please visit https://www.bioskryb.com/.

About BioSkryb Genomics

BioSkryb Genomics is a rapidly growing organization that is transforming single cell molecular discovery and analysis. Through its single cell whole genome and whole transcriptome amplification tools, scientists and clinicians can gain an unprecedented view of the genome, transcriptome, and proteome within a single cell to better understand the drivers, mechanisms, and management of complex disease. The company is headquartered in Durham, North Carolina. For more information, visit bioskryb.com

http://mrem.bernama.com/viewsm.php?idm=47657